Decreased trabecular bone density

Preotact - treatment for decreased trabecular bone density

Osteoporosis is a bone disease that results in decreased trabecular bone density. Decreased trabecular bone density increases risk of bone fracture. The most common areas of bone fracture associated with osteoporosis are the spine, hip and wrist. Often there are no symptoms of osteoporosis before the first fracture occurs.    

Preotact® is a full-length parathyroid hormone (PTH) that provides treatment for postmenopausal osteoporosis patients with decreased trabecular bone density that can increase bone mineral density and decrease bone fracture.

Log in to learn more about decreased trabecular bone density

Nycomed

Nycomed is a European pharmaceutical company that has over 20 years’ experience of working with osteoporosis. Nycomed operates throughout Europe and in fast-growing markets in Latin America, Russia/CIS and Asia-Pacific.

Nycomed provides medicines and products for hospitals, specialists and general practitioners, as well as over-the-counter medicines in selected markets. Offering a broad portfolio of products in a wide range of therapeutic areas, particularly cardiology, gastroenterology, osteoporosis, respiratory, and pain and tissue management.